Phase II trial of ofatumumab plus ESHAP (O-ESHAP) as salvage treatment for patients with relapsed or refractory classical Hodgkin lymphoma after first-line chemotherapy

PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study

(2015) Alison J Moskowitz et al.   LANCET ONCOLOGY

Ofatumumab in relapsed nodular lymphocyte-predominant Hodgkin lymphoma: results of a phase II study from the German Hodgkin study group

(2015) D A Eichenauer et al.   LEUKEMIA

PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma

(2015) Stephen M. Ansell et al.   NEW ENGLAND JOURNAL OF MEDICINE

ESHAP as salvage therapy for relapsed or refractory Hodgkin’s lymphoma

(2014) Jorge Labrador et al.   ANNALS OF HEMATOLOGY

Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma

(2012) A. Younes et al.   BLOOD

Phase 2 study of rituximab-ABVD in classical Hodgkin lymphoma

(2012) Y. L. Kasamon et al.   BLOOD

High-dose chemotherapy in relapsed or refractory Hodgkin lymphoma patients: a reappraisal of prognostic factors

(2012) E Cocorocchio et al.   HEMATOLOGICAL ONCOLOGY

Panobinostat in Patients With Relapsed/Refractory Hodgkin's Lymphoma After Autologous Stem-Cell Transplantation: Results of a Phase II Study

(2012) Anas Younes et al.   JOURNAL OF CLINICAL ONCOLOGY

Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma

(2012) Anas Younes et al.   JOURNAL OF CLINICAL ONCOLOGY

A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma

(2011) T. A. Fehniger et al.   BLOOD

Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma

(2011) C. H. Moskowitz et al.   BLOOD

How I treat relapsed and refractory Hodgkin lymphoma

(2011) J. Kuruvilla et al.   BLOOD

Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma

(2010) A. J. Moskowitz et al.   BLOOD

Different response to salvage chemotherapy but similar post-transplant outcomes in patients with relapsed and refractory Hodgkin's lymphoma

(2010) N. Puig et al.   HAEMATOLOGICA

Salvage chemotherapy with alternating MINE-ESHAP regimen in relapsed or refractory Hodgkin's lymphoma followed by autologous stem-cell transplantation

(2009) C. Fernandez de Larrea et al.   ANNALS OF ONCOLOGY

B-cell Depletion Using an Anti-CD20 Antibody Augments Antitumor Immune Responses and Immunotherapy in Nonhematopoetic Murine Tumor Models

(2008) Samuel Kim et al.   JOURNAL OF IMMUNOTHERAPY

Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphoma

(2007) Yasuhiro Oki et al.   CANCER